Krzysztof Mrozek

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
  2. pmc Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
    Krzysztof Mrozek
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 1228, USA
    J Clin Oncol 30:4515-23. 2012
  3. pmc Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Curr Opin Oncol 20:711-8. 2008
  4. pmc Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 1228, USA
    Semin Oncol 35:365-77. 2008
  5. pmc Cytogenetics and molecular genetics of acute lymphoblastic leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Room 1248B, 300 West Tenth Avenue, Columbus, OH 43210 1228, USA
    Hematol Oncol Clin North Am 23:991-1010, v. 2009
  6. pmc Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience
    Krzysztof Mrozek
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH 43210 1228, USA
    Int J Oncol 33:239-44. 2008
  7. ncbi request reprint Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive, Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Curr Opin Hematol 14:106-14. 2007
  8. pmc Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Krzysztof Mrozek
    Department of Internal Medicine, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, 300 West Tenth Ave, Columbus, OH 43210 1228, USA
    Blood 109:431-48. 2007
  9. doi request reprint Molecular signatures in acute myeloid leukemia
    Krzysztof Mrozek
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, 43210 1228, USA
    Curr Opin Hematol 16:64-9. 2009
  10. ncbi request reprint Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:5705-17. 2005

Detail Information

Publications55

  1. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
    ....
  2. pmc Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
    Krzysztof Mrozek
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 1228, USA
    J Clin Oncol 30:4515-23. 2012
    ..To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML)...
  3. pmc Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Curr Opin Oncol 20:711-8. 2008
    ....
  4. pmc Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 1228, USA
    Semin Oncol 35:365-77. 2008
    ..It is hoped that better understanding of genomic alterations will result in identification of novel therapeutic targets and improved prognosis in patients with complex karyotypes...
  5. pmc Cytogenetics and molecular genetics of acute lymphoblastic leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Room 1248B, 300 West Tenth Avenue, Columbus, OH 43210 1228, USA
    Hematol Oncol Clin North Am 23:991-1010, v. 2009
    ..The article provides a review of modern molecular techniques and their application in the research on the genetics and epigenetics of ALL...
  6. pmc Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience
    Krzysztof Mrozek
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH 43210 1228, USA
    Int J Oncol 33:239-44. 2008
    ..These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies...
  7. ncbi request reprint Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive, Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Curr Opin Hematol 14:106-14. 2007
    ..These genetic alterations affect clinical outcome and may assist in selection of proper treatment. Herein we critically summarize recent clinically relevant molecular genetic studies of cytogenetically normal acute myeloid leukemia...
  8. pmc Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Krzysztof Mrozek
    Department of Internal Medicine, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, 300 West Tenth Ave, Columbus, OH 43210 1228, USA
    Blood 109:431-48. 2007
    ..In this report, we review prognostic genetic findings in karyotypically normal AML and discuss their clinical implications...
  9. doi request reprint Molecular signatures in acute myeloid leukemia
    Krzysztof Mrozek
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, 43210 1228, USA
    Curr Opin Hematol 16:64-9. 2009
    ..In this article, we review the results of recent studies of AML that used microarray-based genome-wide gene-expression and microRNA-expression profiling...
  10. ncbi request reprint Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:5705-17. 2005
    ..Therefore, we sought to determine whether these two cytogenetic groups should also be considered separate entities from a clinical standpoint...
  11. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
    ..To validate ERG overexpression as an adverse predictor and assess its prognostic value in the context of other molecular markers in cytogenetically normal (CN) -acute myeloid leukemia (AML)...
  12. pmc BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:5660-9. 2010
    ....
  13. pmc RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures
    Jason H Mendler
    The Ohio State University, Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 30:3109-18. 2012
    ..To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures...
  14. doi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
    ..A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)...
  15. pmc Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 116:788-92. 2010
    ..Our results indicate that WT1mut CN-AML represents a distinct entity with poor treatment response across age groups. This study has been registered at www.clinicaltrials.gov as #NCT00900224...
  16. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
    ....
  17. ncbi request reprint Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    J Clin Oncol 23:482-93. 2005
    ..Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML)...
  18. pmc Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:4595-602. 2008
    ....
  19. pmc IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:2348-55. 2010
    ....
  20. pmc TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
    Klaus H Metzeler
    The Ohio State University Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:1373-81. 2011
    ....
  21. pmc ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
    Klaus H Metzeler
    Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
    Blood 118:6920-9. 2011
    ..This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1-mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches...
  22. pmc Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Christian Langer
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Suite A434 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH 43210, USA
    J Clin Oncol 27:3198-204. 2009
    ..CONCLUSION MN1 expression independently predicts outcome in CN-AML patients. The MN1 gene- and microRNA-expression signatures suggest biologic features that could be exploited as therapeutic targets...
  23. pmc FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Susan P Whitman
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 116:3622-6. 2010
    ..FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches...
  24. pmc Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 96:1488-95. 2011
    ..To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia...
  25. pmc Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:63-73. 2006
    ..Patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care...
  26. ncbi request reprint Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    John C Byrd
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B302A Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1240, USA
    J Clin Oncol 22:1087-94. 2004
    ..To study the impact of repetitive (three to four courses) versus a single course of high-dose cytarabine (HDAC) consolidation therapy on outcome of patients with acute myeloid leukemia (AML) and inv(16)(p13q22) or t(16;16)(p13;q22)...
  27. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  28. pmc miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
    Ann Kathrin Eisfeld
    The Ohio State University Comprehensive Cancer Center, 300 West 10th Ave, Columbus, OH 43210, USA
    Blood 120:249-58. 2012
    ..The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications...
  29. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  30. ncbi request reprint Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461
    Guido Marcucci
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 22:2410-8. 2004
    ..To our knowledge, ours is the first relatively large study evaluating the usefulness of CRc attained immediately following induction chemotherapy...
  31. pmc Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
    Sebastian Schwind
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 118:4188-98. 2011
    ..We conclude that low MN1 expression confers better prognosis in older CN-AML patients and may refine the European LeukemiaNet classification. Biologic features associated with MN1 expression may help identify new treatment targets...
  32. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
    ..5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD...
  33. pmc FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43240, USA
    Blood 111:1552-9. 2008
    ....
  34. pmc Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower, 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 28:5257-64. 2010
    ....
  35. pmc Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 30:742-50. 2012
    ....
  36. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  37. ncbi request reprint Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA
    Cancer 101:1420-7. 2004
    ..Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease...
  38. doi request reprint New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461
    Alison Walker
    Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Genes Chromosomes Cancer 52:385-401. 2013
    ....
  39. ncbi request reprint Molecular cytogenetic characterization of the KG-1 and KG-1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization
    Krzysztof Mrozek
    Division of Hematology and Oncology, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Genes Chromosomes Cancer 38:249-52. 2003
    ....
  40. pmc inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations
    Sebastian Schwind
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Blood 121:385-91. 2013
    ..We conclude that non-type A fusions associate with distinct clinical and genetic features, including lack of KIT mutations, and a unique gene-expression profile...
  41. pmc Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
    Guido Marcucci
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 31:2086-93. 2013
    ....
  42. doi request reprint MicroRNA expression in acute myeloid leukemia
    Guido Marcucci
    The Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Curr Hematol Malig Rep 4:83-8. 2009
    ..This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance...
  43. pmc Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
    Christopher J Hickey
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:159-69. 2013
    ....
  44. doi request reprint MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 320 West 10th Avenue, Columbus, OH, USA
    Best Pract Res Clin Haematol 22:239-48. 2009
    ..We review herein results of current studies analysing changes of microRNA expression in acute myeloid leukaemia and chronic lymphocytic leukaemia, and discuss their potential biologic, diagnostic and prognostic relevance...
  45. ncbi request reprint Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Int J Oncol 25:143-51. 2004
    ..We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy...
  46. pmc The prognostic and functional role of microRNAs in acute myeloid leukemia
    Guido Marcucci
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA
    Blood 117:1121-9. 2011
    ..We review herein results of current studies analyzing changes of microRNA expression in AML and discuss their potential biologic, diagnostic, and prognostic relevance...
  47. ncbi request reprint Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Hematol 12:68-75. 2005
    ..This article critically reviews the recent literature that addresses the molecular heterogeneity of this group of patients and how this relates to prognostic stratification and novel therapeutic approaches...
  48. pmc Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
    Michael D Radmacher
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Suite A455 Starling Loving Hall, 320 West Tenth Ave, Columbus, OH 43210, USA
    Blood 108:1677-83. 2006
    ..Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML...
  49. pmc Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes
    Claudia D Baldus
    Human Cancer Genetics Program, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 101:3915-20. 2004
    ..Our results highlight the value of molecularly dissecting leukemic cells with complex karyotypes...
  50. ncbi request reprint Cytogenetics in acute leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, The Comprehensive Cancer Center, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, Columbus, OH 43210 1228, USA
    Blood Rev 18:115-36. 2004
    ..This review summarizes current views on clinical relevance of major cytogenetic findings in adult AML and ALL...
  51. ncbi request reprint Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q
    Krzysztof Mrozek
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Genes Chromosomes Cancer 34:137-53. 2002
    ..We conclude that SKY considerably enhances the accuracy of karyotype interpretation, and that amplification of chromosomal material may play a greater role in leukemogenesis than has been recognized...
  52. ncbi request reprint Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions
    Clara D Bloomfield
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 12:3564s-71s. 2006
    ....
  53. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    ..To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22)...
  54. ncbi request reprint Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
    Int J Oncol 21:1041-51. 2002
    ..We conclude that in de novo adult AML patients not receiving SCT, IT(C) appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis...
  55. ncbi request reprint 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop
    Clara D Bloomfield
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Genes Chromosomes Cancer 33:362-78. 2002
    ..We conclude that among t-MDS/t-AL patients with balanced aberrations, 11q23 translocations are an independent adverse risk factor. Although BMT is the current therapy of choice, new treatment is required...